| Patent Number |
Title Of Patent |
Date Issued |
| 7608598 |
Use of lipid conjugates in the treatment of conjunctivitis |
October 27, 2009 |
| In one embodiment, the invention provides a method of suppressing, inhibiting, preventing, or treating conjunctivitis in a subject, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound via an ester or amide bond to a physiologically accepta |
| 7504384 |
Use of lipid conjugates in the treatment of infection |
March 17, 2009 |
| This invention provides compounds and methods of use thereof in suppressing, inhibiting, preventing, or treating a pathogenic effect on a cell, including, inter alia, infection with intracellular pathogens. Also provided are compounds and methods of use thereof in suppressing, inhibi |
| 7393938 |
Use of lipid conjugates in the treatment of diseases |
July 1, 2008 |
| This invention provides compounds represented by the structure of the general formula (A): ##STR00001## wherein L is a lipid or a phospholipid, Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol, Y is either nothing or a spacer group ranging in length from 2 t |
| 7141552 |
Use of lipid conjugates in the treatment of diseases |
November 28, 2006 |
| The invention provides a method for treating a subject suffering from an intestinal disease, including, inter alia, Crohn's disease, ulcerative colitis, immuno-inflammatory intestinal injury, drug-induced enteropathy and ischemia-induced intestinal injury. This invention further provides |
| 7101859 |
Use of lipid conjugates in the treatment of diseases |
September 5, 2006 |
| The invention provides novel methods for treating disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE |
| 7034006 |
Use of lipid conjugates in the treatment of disease |
April 25, 2006 |
| The invention provides novel methods for treating disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE |
| 5656501 |
Flow cell device for monitoring blood or other cell suspension under flow |
August 12, 1997 |
| A flow cell for monitoring blood or any other cell suspension under flow prises a rigid transparent base having a pair of holes with inlets and outlets. One hole transfers the cell suspension from a supply to a flow channel and the other hole transfers the tested suspension back from th |
| 5064817 |
Phospholipase A.sub.2 inhibiting compositions and their use |
November 12, 1991 |
| Inhibitors of phospholipase A.sub.2 activity at the cell-surface membrane whose molecular structure comprises a cell-permeable PLA.sub.2 -inhibitor moiety covalently bonded directly or indirectly to a physiologically acceptable carrier moiety which is effective to inhibit cell intern |
